New drug trial aims to stop dangerous bleeding in heart stent patients
NCT ID NCT07479056
Summary
This study is testing whether a new stomach-protecting drug called fexuprazan can prevent serious stomach bleeding in high-risk patients. The participants are people who have had a heart stent placed and must take two blood-thinning medications, which increases their risk of bleeding. Researchers will compare fexuprazan against standard care to see if it better protects the stomach and upper digestive tract.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DISEASES OF THE CIRCULATORY SYSTEM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
RECRUITINGSeoul, Eunpyeong-gu, 03312, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.